1.
Journal of Experimental Hematology
;
(6): 1701-1705, 2019.
Artigo
em Chinês
| WPRIM
| ID: wpr-775662
RESUMO
Abstract B cell maturation antigen (BCMA) is an ideal target for precise treatment due to its highly selective expression on malignant myeloma cells. This review summarizes briefly the advances in the latest research progress on biological activity of BCMA, its significance as a biomarker and immunotherapy direcited against BCMA, such as bispecific antibodies, antibody drug conjugates, chimeric antigen receptor T cell therapy against mature B cell antigens.